WebAug 30, 2024 · Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor — a class of drugs that causes the body to excrete sugar in urine. In addition to controlling blood sugar in patients with diabetes, SGLT-2 inhibitors have been shown to provide significant cardiovascular and kidney disease benefits. WebJan 10, 2024 · This AHA scientific statement update focuses on (1) the evidence and clinical utility of newer antihyperglycemic agents in improving glycemic control and reducing cardiovascular events in diabetes; (2) the impact of blood pressure control on cardiovascular events in diabetes; and (3) the role of newer lipid-lowering therapies in …
What is the Best Diabetes Medication? One that Can Protect Your Heart …
Web10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes 2024. Diabetes Care 2024;42(Suppl. 1): S103–S123 Antiplatelet Agents • Consider … WebDec 4, 2024 · Atherosclerotic cardiovascular disease (ASCVD)—defined as coronary heart disease (CHD), cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin—is the leading … how to treat a lingering cough after covid
Top 20 Research Studies of 2024 for Primary Care Physicians
WebApr 12, 2024 · Despite the availability of many glucose-lowering drugs, patients with type 2 diabetes mellitus (T2DM) often do not achieve the desired effect, and cardiovascular complications remain the leading cause of death in this group of patients. Recently, more and more attention has been paid to the properties of drugs, with particular emphasis on … WebThere are two classes of type 2 diabetes medications that have received approval to treat heart disease . “Patients who take these drugs have their risk of death from heart … WebApr 1, 2024 · Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 … order of service pallet